Home Cart Sign in  
Chemical Structure| 3681-93-4 Chemical Structure| 3681-93-4

Structure of Vitexin
CAS No.: 3681-93-4

Chemical Structure| 3681-93-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vitexin exhibits inhibition of carbohydrate hydrolase with IC50 of 244 μM and shows antioxidant activity in DPPH bleaching assay (IC50 = 24.2 μM). It is an apigenin flavone c-glycosidea isolated and purified from the seeds of Vitex trifolia L. with antinociceptive, antimyeloperoxidase, and anti-inflammatory activities.

Synonyms: Orientoside; Apigenin-8-C-glucoside; Vitexin, Apigenin 8-C-glucoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Vitexin

CAS No. :3681-93-4
Formula : C21H20O10
M.W : 432.38
SMILES Code : O=C1C=C(C2=CC=C(O)C=C2)OC3=C([C@@H]4O[C@H](CO)[C@H]([C@@H]([C@H]4O)O)O)C(O)=CC(O)=C31
Synonyms :
Orientoside; Apigenin-8-C-glucoside; Vitexin, Apigenin 8-C-glucoside
MDL No. :MFCD00017456
InChI Key :SGEWCQFRYRRZDC-VPRICQMDSA-N
Pubchem ID :5280441

Safety of Vitexin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 20, 10, 5 µM 48 hours Detect the transcriptional activation effect of VDR on the CYP24A1 promoter PMC11395219
RAW 264.7 cells Different concentration gradients Detect VDR gene levels PMC11395219
THP-1 cells 100 µM 2 hours Validate the binding of Vitexin to VDR protein through CETSA and DARTS experiments PMC11395219
HK2 cells 100 µM 24 hours To study the effect of Vitexin on ferroptosis in HK2 cells, results showed that Vitexin significantly inhibited erastin-induced ferroptosis. PMC10612207
T lymphocytes 200 µM 96 hours Inhibited T lymphocyte proliferation, especially CD4+ T cells (16.95±1.11% vs 77.17±6.29%), induced late apoptosis/necrosis (83±3.3% vs 53.6±3.1%) and mitochondrial depolarization PMC9405454
SW620 cells 10 and 20 μM 48 hours Chrysin inhibits EMT and malignant progression of colorectal cancer cells by inhibiting the COMP/TAGLN complex. PMC2752044
HCT-8 cells 10 and 20 μM 48 hours Chrysin inhibits EMT and malignant progression of colorectal cancer cells by inhibiting the COMP/TAGLN complex. PMC2752044
HCT116 cells 10 and 20 μM 48 hours Chrysin inhibits EMT and malignant progression of colorectal cancer cells by inhibiting the COMP/TAGLN complex. PMC2752044

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Subcutaneous xenograft model Intraperitoneal injection 40 or 80 mg/kg Twice every other day for 2-3 weeks VB1 significantly inhibited the growth of subcutaneous xenografts without significant effects on body weight PMC6219156
C57BL/6J mice Unilateral ureteral obstruction (UUO) and unilateral ischemia–reperfusion (UIR) models Intragastric administration 30 mg/kg/day Once daily for 21 days To evaluate the effect of Vitexin on renal tubular injury, interstitial fibrosis, and inflammation in CKD model mice, results showed that Vitexin significantly ameliorated these pathological changes. PMC10612207
Mice Carotid partial ligation model and hyperlipidemic mice model Intraperitoneal injection 5, 10, or 20 mg/kg Twice a week for 1 or 4 weeks Inhibited disturbed flow-induced endothelial inflammation and neointimal formation, ameliorated atherosclerosis PMC8640790
C57BL/6J mice High-fat diet-induced obesity model Oral 6 mg/kg bw/day and 30 mg/kg bw/day Once daily for 13 weeks Vitexin significantly slowed body weight gain, improved glucose tolerance, regulated blood lipid levels, and downregulated the expression of obesity-related genes (ppar-α, ppar-γ, fas). Additionally, the treatment groups showed a significant improvement in gut microbiota diversity. PMC11951210
Kunming mice D-galactose-induced aging mouse model Intragastric administration 40, 20, or 10 mg/kg Once daily for 8 weeks Vitexin improved the general medical conditions of aging mice, significantly increased brain weights, enhanced antioxidant enzyme activities in serum and tissues, reduced lipid peroxidation products and lipofuscin accumulation, and improved neuronal ultrastructure. PMC4200723

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01647984 Ventricular and Atrial Extrasy... More >>toles Less << Phase 4 Completed - Italy ... More >> Ambulatorio Ipertensione e Unità Coronarica Federico II University Naples, Italy, 80131 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.56mL

2.31mL

1.16mL

23.13mL

4.63mL

2.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Xue HF, Ying ZM, et al. Hepatic, gastric, and intestinal first-pass effects of vitexin in rats. Pharm Biol. 2014 Aug;52(8):967-71.

[2]Yang SH, Liao PH, et al. The novel p53-dependent metastatic and apoptotic pathway induced by vitexin in human oral cancer OC2 cells. Phytother Res. 2013 Aug;27(8):1154-61..

[3]Abu Bakar AR, Manaharan T, Merican AF, Mohamad SB. Experimental and computational approaches to reveal the potential of Ficus deltoidea leaves extract as α-amylase inhibitor. Nat Prod Res. 2018 Feb;32(4):473-476

[4]Babaei F, Moafizad A, Darvishvand Z, Mirzababaei M, Hosseinzadeh H, Nassiri-Asl M. Review of the effects of vitexin in oxidative stress-related diseases. Food Sci Nutr. 2020 Apr 14;8(6):2569-2580

[5]Jiang J, Dai J, Cui H. Vitexin reverses the autophagy dysfunction to attenuate MCAO-induced cerebral ischemic stroke via mTOR/Ulk1 pathway. Biomed Pharmacother. 2018 Mar;99:583-590

[6]Li Y, Sun Q, Li H, Yang B, Wang M. Vitexin suppresses renal cell carcinoma by regulating mTOR pathways. Transl Androl Urol. 2020 Aug;9(4):1700-1711

[7]de Oliveira DD, da Silva CP, Iglesias BB, Beleboni RO. Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models. Front Pharmacol. 2020 Aug 11;11:1181

[8]Li XS, Tang XY, Su W, Li X. Vitexin protects melanocytes from oxidative stress via activating MAPK-Nrf2/ARE pathway. Immunopharmacol Immunotoxicol. 2020 Dec;42(6):594-603

[9]Rosa SI, Rios-Santos F, Balogun SO, Martins DT. Vitexin reduces neutrophil migration to inflammatory focus by down-regulating pro-inflammatory mediators via inhibition of p38, ERK1/2 and JNK pathway. Phytomedicine. 2016 Jan 15;23(1):9-17

 

Historical Records

Categories